The state of Tennessee currently has 14 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Nashville, Memphis, Knoxville and Chattanooga.
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis \[UC\]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: GastroOne, Germantown, Tennessee
Conditions: Ulcerative Colitis, Crohn Disease
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Ulcerative Colitis